European beauty forecast
This article was originally published in The Rose Sheet
Executive Summary
According to new research from Mintel, the combined health and beauty sectors in Germany, France, UK, Italy, Spain and the Netherlands are expected to grow 12% to roughly $197.4 bil. over the next five years. "Both manufacturers and retailers have continued to innovate despite difficult economic circumstances across Europe, trying for the ultimate breakthrough product or beauty solution, and it is fantastic that this is reflected in such a positive forecast for the industry," says Mintel Head Consultant Nica Lewis. Health and beauty sales in France and the Netherlands will lead the way for growth, Mintel predicts, with five-year rates of 18% and 15%, respectivelyYou may also be interested in...
Sanofi Bets Big On IO With Synthorx Buy
The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.
Global Industry Hails Bioequivalence Progress
For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.
Generics Leaders Trade Places At The Top
In 2019, Mylan moved up to become the world’s leading generics, biosimilars and OTC player, according to Informa Pharma Intelligence’s latest global rankings. Sandoz has surpassed troubled Teva into second place but is set to surrender that position following the sale of its US solid-dose and dermatology business to India’s Aurobindo.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: